secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033504
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology reduces workforce by 30%; President and CSO Pons to depart April 2025
--------------------------------------------------------------------------------

- Board approved ~30% workforce reduction to prioritize pipeline and extend cash runway; substantially complete by May 2025.
- Estimated $2.2 million in severance and benefits costs, recognized in Q1 2025.
- President and CSO Jaume Pons will depart in April 2025; eligible for annual salary and 12 months COBRA.
- No replacement named; position eliminated; transition consulting agreement expected.
- Reduction part of pipeline prioritization and cash preservation strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/0000950170-25-033504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/alxo-20250228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer